title: Decreased level of recent thymic emigrants in CD4+ and CD8+T cells from CML patients.
abstract: BACKGROUND
  T-cell immunodeficiency is a common feature in cancer patients, which may relate to initiation and development of tumor. Based on our previous finding, to further characterize the immune status, T cell proliferative history was analyzed in CD4+ and CD8+ T cells from chronic myeloid leukemia (CML) patients.
  
  
  METHODS
  Quantitative analysis of deltaRec-psiJalpha signal joint T cell receptor excision circles (sjTRECs) was performed in PBMCs, CD3+, CD4+ and CD8+T cells by real-time PCR, and the analysis of 23 TRBV-D1 sjTRECs was performed by semi-nested PCR. Forty eight CML cases in chronic phase (CML-CP) were selected for this study and 17 healthy individuals served as controls.
  
  
  RESULTS
  The levels of deltaRec-psiJalpha sjTRECs in PBMCs, CD3+, CD4+, and CD8+ T cells were significantly decreased in CML patients, compared with control groups. Moreover, the numbers of detectable TRBV subfamily sjTRECs, as well as the frequency of particular TRBV-BD1 sjTRECs in patients with CML were significantly lower than those from healthy individuals.
  
  
  CONCLUSIONS
  We observed decreased levels of recent thymic emigrants in CD4+ and CD8+ T cells that may underlay the persistent immunodeficiency in CML patients.
authors.affiliation: Institute of Hematology, Medical College, Jinan University, Guangzhou, 510632, China. yangqiuli@hotmail.com
authors.forename: Yangqiu
authors.initials: Y
authors.lastname: Li
authors.forename: Suxia
authors.initials: S
authors.lastname: Geng
authors.forename: Qingsong
authors.initials: Q
authors.lastname: Yin
authors.forename: Shaohua
authors.initials: S
authors.lastname: Chen
authors.forename: Lijian
authors.initials: L
authors.lastname: Yang
authors.forename: Xiuli
authors.initials: X
authors.lastname: Wu
authors.forename: Bo
authors.initials: B
authors.lastname: Li
authors.forename: Xin
authors.initials: X
authors.lastname: Du
authors.forename: Christian A
authors.initials: CA
authors.lastname: Schmidt
authors.forename: Grzegorz K
authors.initials: GK
authors.lastname: Przybylski
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D016022:Case-Control Studies; D002465:Cell Movement / Q000276:immunology*; D004270:DNA, Circular / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000473:pathology*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology* / Q000473:pathology*; D055815:Young Adult
chemical_list: D004270:DNA, Circular; D016693:Receptors, Antigen, T-Cell, alpha-beta
references.citation: J Exp Med. 1999 Aug 16;190(4):479-86
references.pmid: 10449519
references.citation: Nature. 1998 Dec 17;396(6712):690-5
references.pmid: 9872319
references.citation: Br J Haematol. 2003 Sep;122(5):795-801
references.pmid: 12930391
references.citation: Zhonghua Xue Ye Xue Za Zhi. 2005 Jul;26(7):413-6
references.pmid: 16251024
references.citation: J Exp Med. 2002 Mar 18;195(6):789-94
references.pmid: 11901204
references.citation: Blood. 2003 Dec 15;102(13):4600-7
references.pmid: 12933579
references.citation: J Endocrinol. 2003 Mar;176(3):305-11
references.pmid: 12630915
references.citation: J Immunol. 1994 Nov 1;153(9):4281-90
references.pmid: 7930628
references.citation: Nature. 1988 Sep 8;335(6186):170-4
references.pmid: 2842691
references.citation: Eur J Haematol. 2003 May;70(5):333-45
references.pmid: 12694173
references.citation: Clin Exp Immunol. 2001 Sep;125(3):409-13
references.pmid: 11531948
references.citation: Immunol Today. 1995 Apr;16(4):176-81
references.pmid: 7734044
references.citation: Hematology. 2009 Apr;14(2):95-100
references.pmid: 19298721
references.citation: Int Immunopharmacol. 2003 Aug;3(8):1061-71
references.pmid: 12860163
references.citation: J Immunother. 1998 Sep;21(5):363-70
references.pmid: 9789198
references.citation: Lancet. 2000 May 27;355(9218):1875-81
references.pmid: 10866444
references.citation: Target Oncol. 2009 Jan;4(1):3-10
references.pmid: 19343297
references.citation: J Appl Genet. 2007;48(4):397-404
references.pmid: 17998599
references.citation: J Hematol Oncol. 2010 Apr 09;3:14
references.pmid: 20377918
references.citation: Cancer Immunol Immunother. 2009 Jul;58(7):1047-55
references.pmid: 19018534
references.citation: Transpl Immunol. 2007 Nov;18(2):151-8
references.pmid: 18005861
references.citation: Leukemia. 1996 Mar;10(3):494-7
references.pmid: 8642868
references.citation: Int J Cancer. 2002 Sep 1;101(1):74-7
references.pmid: 12209591
references.citation: J Mol Med (Berl). 2001 Nov;79(11):631-40
references.pmid: 11715066
references.citation: Hematology. 2005 Aug;10(4):297-305
references.pmid: 16085542
references.citation: J Immunol Methods. 2000 Apr 3;237(1-2):187-97
references.pmid: 10725462
references.citation: J Immunol. 1997 Feb 1;158(3):1482-9
references.pmid: 9013995